[Increasing incidence of angioedema without urticaria—clinical features]
Asja Stipić Marković, Martina Janzeković
Acta Medica Croatica: C̆asopis Hravatske Akademije Medicinskih Znanosti 2011, 65 (2): 119-27
The causes of angioedema (AE), a self-limited, localized swelling of subcutaneous tissue or mucosa unaccompanied by urticaria, are diverse. The commonly applied label of "allergic" is frequently wrong and standard anti-allergic therapy can be ineffective. Types of AE could be categorized according to mediators which mediate vascular leakage: bradykinin AE (hereditary, acquired, angiotensin-converting enzyme inhibitor (ACEi)-related), histamine AE (allergic etiology), and various mediators mediated AE (pseudoallergic reaction to non-steroidal anti-inflammatory drugs). Idiopathic AE is a poorly understood syndrome. The growing relevance of AE without urticaria has been highlighted; angioedema is the most common cause of hospital admission among all acute allergic diseases. The diagnosis of AE is based on the presence of family history (hereditary), absence of family history with the onset during or after the fourth decade of life (acquired C1lnh deficiency), and treatment with ACEi (ACEi-related angioedema). About 0.1%-0.7% of patients taking ACEi develop angioedema as a well-documented but still frequently unrecognized side effect of drugs. Laboratory diagnosis is enabled by measuring serum levels of C1lnh antigen or C1lnh function. Type 1 (hereditary angioedema (HAE) was diagnosed when both antigenic and functional levels of C1lnh were below 50% of normal, and type 2 when functional levels of C1lnh were low, along with antigenic levels normal or higher. ACEi-related AE is diagnosed when AE recurs during therapy and disappears upon withdrawal. Symptoms may appear several years after therapy introduction. Severe acute attacks should be treated with C1lnh concentrate and icatibant, a selective and specific antagonist of bradykinin B2 receptors. Prophylaxis with attenuated androgens (danazol, stanazolol, oxandrolone) is effective in preventing symptom development.
Angioedema: etiology, pathophysiology, current and emerging therapies. Lawrence M Lewis Journal of Emergency Medicine 2013, 45 (5): 789-96
[Bradykinin mediated angioedema]. L Bouillet, I Boccon-Gibod, C Massot La Revue de Médecine Interne 2011, 32 (4): 225-31
Hereditary angioedema in childhood: an approach to management. Didier G Ebo, Marjoke M Verweij, Kathleen J De Knop, Margo M Hagendorens, Chris H Bridts, Luc S De Clerck, Wim J Stevens Paediatric Drugs 2010 August 1, 12 (4): 257-68
[Angioedema]. H F Merk Der Hautarzt; Zeitschrift Für Dermatologie, Venerologie, und Verwandte Gebiete 2007, 58 (12): 1041-5
Prominent features of allergic angioedema on oral mucosa. Tomislav Duvancić, Liborija Lugović-Mihić, Ante Brekalo, Mirna Situm, Ana Sinković Acta Clinica Croatica 2011, 50 (4): 531-8
Many faces of angioedema: focus on the diagnosis and management of abdominal manifestations of hereditary angioedema. Ugochukwu C Nzeako, Hilary J Longhurst European Journal of Gastroenterology & Hepatology 2012, 24 (4): 353-61
Clinical and laboratory characteristics that differentiate hereditary angioedema in 72 patients with angioedema. Isao Ohsawa, Daisuke Honda, Seiji Nagamachi, Atsuko Hisada, Mamiko Shimamoto, Hiroyuki Inoshita, Satoshi Mano, Yasuhiko Tomino Allergology International: Official Journal of the Japanese Society of Allergology 2014, 63 (4): 595-602
Pathophysiology of hereditary angioedema. Bruce L Zuraw, Sandra C Christiansen American Journal of Rhinology & Allergy 2011, 25 (6): 373-8
Icatibant: a novel approach to the treatment of angioedema related to the use of angiotensin-converting enzyme inhibitors. Mauro Gallitelli, Michele Alzetta American Journal of Emergency Medicine 2012, 30 (8): 1664.e1-2
Therapeutic efficacy of icatibant in angioedema induced by angiotensin-converting enzyme inhibitors: a case series. Murat Bas, Jens Greve, Klaus Stelter, Henning Bier, Thomas Stark, Thomas K Hoffmann, Georg Kojda Annals of Emergency Medicine 2010, 56 (3): 278-82